p-value was calculated using two-tailed Learners t-test. miR-146a-/- mice at 2 and 17 weeks HFD. (F) Evaluation of percent putting on Seviteronel weight in man and feminine WT and miR-146a-/- mice on HFD for 11 weeks. (G-I) C57BL6/J (blue) and miR-146a-/- (green) mice bought from Jackson Laboratories had been positioned on HFD and the next had been assessed: (G) percent putting on weight, (H) bodyweight gain (in grams), and (I) meals consumption assessed both night and day at 0, 3 and 18 weeks HFD in metabolic chambers. p-values had been computed using two-tailed Learners t-test. *p 0.05; **p 0.01; ***p 0.001; ****p 0.0001.(TIF) pgen.1007970.s001.tif (745K) GUID:?ACEE7D7C-A5E8-48A8-9C8D-98FF4C4B1CC6 S2 Fig: miR-146a and BAT weight and gene expression. (A-C) qRT-PCR appearance data from BAT examples of young, neglected WT (blue) or miR-146a-/- (green) mice in accordance with L32 appearance in (A) BAT activation genes, (B) Lipogenesis genes, and (C) inflammatory immune system genes. (D) Fat (g) of BAT examples from WT or miR-146a-/- mice. (E) qRT-PCR appearance of miR-146a in accordance with 5s in WT (blue) or miR-146a-/- (green) BAT examples. (F) qRT-PCR appearance data from BAT examples of WT (blue) or miR-146a-/- (green) mice pursuing HFD, in accordance with L32 expression for several BAT and inflammatory genes. Data are proven as mean SEM Seviteronel (n = 5). p-value was computed using two-tailed Learners t-test. *p 0.05; **p 0.01.(TIF) pgen.1007970.s002.tif (507K) GUID:?AF3A5180-D10F-4DA6-AACE-48005E8EF8BE S3 Fig: miR-146a protects against high blood sugar levels during diet-induced obesity but will not alter pancreatic architecture. (A) WT and miR-146a-/- mice on NCD or HFD had been injected with blood sugar at 0 a few minutes and blood sugar levels had been measured as time passes for 120 a few minutes. (B) Blood sugar of 6-hour fasted WT and miR-146a-/- mice on NCD or HFD. (C) H&E staining of consultant parts of pancreas at week 14 of diet plan treatment. Data are proven as meanSEM or as specific mice; p-value was computed using two-tailed Learners t-test. *p 0.05; **p 0.01.(TIF) pgen.1007970.s003.tif (2.2M) GUID:?26883EC6-0FA2-409D-AD1B-0109ED88656D S4 Fig: Increased putting on weight by miR-146a-/- mice during DIO isn’t influenced by miR-155. (A) Percent putting on weight as time passes of diet plan in WT, miR-155-/-, miR-146a-/-, and DKO mice on HFD. (B) Bodyweight (in grams) of WT, miR-155-/-, miR-146a-/-, and DKO mice as time passes of diet plan. (C) Blood sugar degrees of WT, miR-155-/-, miR-146a-/-, and DKO mice carrying out a six-hour fast, at 15 weeks HFD. (D) Fat of reproductive, visceral unwanted fat pads gathered from WT, miR-155-/-, miR-146a-/-, and DKO mice pursuing HFD. (E) TD-NMR body structure measurement displaying percent surplus fat of WT, miR-155-/-, miR-146a-/- mice at week 14 HFD. (F) Percent trim mass of total bodyweight in WT, miR-155-/-, miR-146a-/-, and DKO mice at week 14 HFD. Data are proven as meanSEM (n = 5); p-value was computed using two-tailed Learners t-test. *p 0.05; **p 0.01; ***p 0.001; ****p 0.0001.(TIF) pgen.1007970.s004.tif (608K) GUID:?B15F5E2B-C4Compact disc-4D56-A7E7-B5CF601903BE S5 Fig: GSEA of RNA-seq data from miR-146a-/- and WT mouse ATMs in NCD or HFD. (A) Percentages of live, singlet Compact disc45+ cells positive for Compact disc11b and F4/80 markers, gathered in the SVF of VAT in WT and miR-146a-/- mice given HFD or NCD. (B) Final number of live, singlet, Compact disc45+ cells positive for Compact disc11b and F4/80 markers, gathered in the SVF of VAT in WT and miR-146a-/- mice given NCD or HFD. (C) Percentage of live, singlet Compact disc45+ cells and percentage of Compact disc45+ B (B220+) and T (Compact disc3e+) cells, in the SVF of VAT in WT and miR-146a-/- mice given HFD. (D) Gene Pieces considerably upregulated in miR-146a-/- HFD mice weighed against WT, regarding to GSEA. (E) Gene pieces considerably upregulated in miR-146a-/- NCD mice weighed against WT, regarding to GSEA. NES = normalized enrichment rating; FDR = fake discovery price, where FDR 0.25 is significant statistically. For the and b, p-values had been computed using two-tailed Learners t-test. *p 0.05; ns = not really significant.(TIF) pgen.1007970.s005.tif (1.7M) GUID:?906B9D99-CB27-43A4-9F4D-D45C98AAFDE6 S1 Desk: Materials desk listing all components found in this publication. (PDF) pgen.1007970.s006.pdf (109K) Seviteronel GUID:?3E129077-F6A2-42DE-9AED-314FF462917B S2 Desk: Underlying numeric.*p 0.05; **p 0.01; ***p 0.001; ****p 0.0001. (TIF) Click here for extra data document.(745K, tif) S2 BAT and FigmiR-146a fat and gene expression. 2 and 17 weeks HFD. (F) Evaluation of percent putting on weight in man and feminine WT and miR-146a-/- mice on HFD for 11 weeks. (G-I) C57BL6/J (blue) and miR-146a-/- (green) mice bought from Jackson Laboratories had been positioned on HFD and the next had been assessed: (G) percent putting on weight, (H) bodyweight gain (in grams), and (I) meals consumption assessed both night and day at 0, 3 and 18 weeks HFD in metabolic chambers. p-values had been computed using two-tailed Learners t-test. *p 0.05; **p 0.01; ***p 0.001; ****p 0.0001.(TIF) pgen.1007970.s001.tif (745K) GUID:?ACEE7D7C-A5E8-48A8-9C8D-98FF4C4B1CC6 S2 Fig: miR-146a and BAT weight and gene expression. (A-C) qRT-PCR appearance data from BAT examples of young, neglected WT (blue) or miR-146a-/- (green) mice in accordance with L32 appearance in (A) BAT activation genes, (B) Lipogenesis genes, and (C) inflammatory immune system genes. (D) Fat (g) of BAT examples from WT or miR-146a-/- mice. (E) qRT-PCR appearance of miR-146a in accordance with 5s in WT (blue) or miR-146a-/- (green) BAT examples. (F) qRT-PCR appearance data from BAT examples of WT (blue) or miR-146a-/- (green) mice pursuing HFD, in accordance with L32 expression for several BAT and inflammatory genes. Data are proven as mean SEM (n = 5). p-value was computed using two-tailed Learners t-test. *p 0.05; **p 0.01.(TIF) pgen.1007970.s002.tif (507K) GUID:?AF3A5180-D10F-4DA6-AACE-48005E8EF8BE S3 Fig: miR-146a protects against high blood sugar levels during diet-induced obesity but will not alter pancreatic architecture. (A) WT and miR-146a-/- mice on NCD or HFD had been injected with blood sugar at 0 a few minutes and blood sugar levels had been measured as time passes for 120 a few minutes. (B) Blood sugar of 6-hour fasted WT and miR-146a-/- mice on NCD or HFD. (C) H&E staining of consultant parts of pancreas at week 14 of diet plan treatment. Data are proven as meanSEM or as specific mice; p-value was computed using two-tailed Learners t-test. *p 0.05; **p 0.01.(TIF) pgen.1007970.s003.tif (2.2M) Seviteronel GUID:?26883EC6-0FA2-409D-AD1B-0109ED88656D S4 Fig: Increased putting on weight by miR-146a-/- mice during DIO isn’t influenced by miR-155. (A) Percent putting on weight as time passes of diet plan in WT, miR-155-/-, miR-146a-/-, and DKO mice on HFD. (B) Bodyweight (in grams) of WT, miR-155-/-, miR-146a-/-, and DKO mice as time passes of diet plan. (C) Blood sugar degrees of WT, miR-155-/-, miR-146a-/-, and DKO mice carrying out a six-hour fast, at 15 weeks HFD. (D) Fat of reproductive, visceral unwanted fat pads gathered from WT, miR-155-/-, miR-146a-/-, and DKO mice pursuing HFD. (E) TD-NMR body structure measurement displaying percent surplus fat of WT, miR-155-/-, miR-146a-/- mice at week 14 HFD. (F) Percent trim mass of total bodyweight in WT, miR-155-/-, miR-146a-/-, and DKO mice at week 14 HFD. Data are proven as meanSEM (n = 5); p-value was computed using two-tailed Learners t-test. *p 0.05; **p 0.01; ***p 0.001; ****p 0.0001.(TIF) pgen.1007970.s004.tif (608K) GUID:?B15F5E2B-C4Compact disc-4D56-A7E7-B5CF601903BE S5 Fig: GSEA of RNA-seq data from miR-146a-/- and WT mouse ATMs in NCD or HFD. (A) Percentages of live, singlet Compact disc45+ cells positive for Compact disc11b and F4/80 markers, gathered in the SVF of VAT in WT and miR-146a-/- mice given NCD or HFD. (B) Final number of live, singlet, Compact disc45+ cells positive for Compact disc11b and F4/80 markers, gathered in the SVF of VAT in WT and miR-146a-/- mice given NCD or HFD. (C) Percentage of live, singlet Compact disc45+ cells and percentage of Compact disc45+ B (B220+) and T (Compact disc3e+) cells, in the SVF of VAT in WT and miR-146a-/- mice given HFD. (D) Gene Pieces considerably upregulated in miR-146a-/- HFD mice weighed against WT, regarding to GSEA. (E) Gene pieces considerably upregulated in miR-146a-/- NCD mice compared with WT, according to GSEA. NES = normalized enrichment score; FDR = false discovery rate, where FDR 0.25 is statistically significant. For a and b, p-values were calculated using two-tailed Students t-test. *p 0.05; ns = not significant.(TIF) pgen.1007970.s005.tif (1.7M) GUID:?906B9D99-CB27-43A4-9F4D-D45C98AAFDE6 S1 Table: Materials table listing all materials.(B) Percent weight gain over time of WT and miR-146a-/- mice on NCD. (G) percent weight gain, (H) body weight gain (in grams), and (I) food consumption measured both day and night at 0, 3 and 18 weeks HFD in metabolic chambers. p-values were calculated using two-tailed Students t-test. *p 0.05; **p 0.01; ***p 0.001; ****p 0.0001.(TIF) pgen.1007970.s001.tif (745K) GUID:?ACEE7D7C-A5E8-48A8-9C8D-98FF4C4B1CC6 S2 Fig: miR-146a and BAT weight and gene expression. (A-C) qRT-PCR expression data from BAT samples of young, untreated WT (blue) or miR-146a-/- (green) mice relative to L32 expression in (A) BAT activation genes, (B) Lipogenesis genes, and (C) inflammatory immune genes. (D) Weight (g) of BAT samples from WT or miR-146a-/- mice. (E) qRT-PCR expression of miR-146a relative to 5s in WT (blue) or miR-146a-/- (green) BAT samples. (F) qRT-PCR expression data from BAT samples of WT (blue) or miR-146a-/- (green) mice following HFD, relative to L32 expression for a number of BAT and inflammatory genes. Data are shown as mean SEM (n = 5). p-value was calculated using two-tailed Students t-test. *p 0.05; **p 0.01.(TIF) pgen.1007970.s002.tif (507K) GUID:?AF3A5180-D10F-4DA6-AACE-48005E8EF8BE S3 Fig: miR-146a protects against high blood glucose levels during diet-induced obesity but does not alter pancreatic architecture. (A) WT and miR-146a-/- mice on NCD or HFD were injected with glucose at 0 minutes and blood glucose levels were measured over time for 120 minutes. (B) Blood glucose of 6-hour fasted WT and miR-146a-/- mice on NCD or HFD. (C) H&E staining of representative sections of pancreas at week 14 of diet treatment. Data are shown as meanSEM or as individual mice; p-value was calculated using two-tailed Students t-test. *p 0.05; **p 0.01.(TIF) pgen.1007970.s003.tif (2.2M) GUID:?26883EC6-0FA2-409D-AD1B-0109ED88656D S4 Fig: Increased weight gain by miR-146a-/- mice during DIO is not dependent upon miR-155. (A) Percent weight gain over time of diet in WT, miR-155-/-, miR-146a-/-, and DKO mice on HFD. (B) Body weight (in grams) of WT, miR-155-/-, miR-146a-/-, and DKO mice over time of diet. (C) Blood glucose levels of WT, miR-155-/-, miR-146a-/-, and DKO mice following a six-hour fast, at 15 weeks HFD. (D) Weight of reproductive, visceral excess fat pads harvested from WT, miR-155-/-, miR-146a-/-, and DKO mice following HFD. (E) TD-NMR body composition measurement showing percent body fat of WT, miR-155-/-, miR-146a-/- mice at week 14 HFD. (F) Percent lean mass of total body weight in WT, miR-155-/-, miR-146a-/-, and DKO mice at week 14 HFD. Data are shown as meanSEM (n = 5); p-value was calculated using two-tailed Students t-test. *p 0.05; **p 0.01; ***p 0.001; ****p 0.0001.(TIF) pgen.1007970.s004.tif (608K) GUID:?B15F5E2B-C4CD-4D56-A7E7-B5CF601903BE S5 Fig: GSEA of RNA-seq data from miR-146a-/- and WT mouse ATMs on NCD or HFD. (A) Percentages of live, singlet CD45+ cells positive for CD11b and F4/80 markers, collected from the SVF of VAT in WT and miR-146a-/- mice fed NCD or HFD. (B) Total number of live, singlet, CD45+ cells positive for CD11b and F4/80 markers, collected from the SVF of VAT in WT and miR-146a-/- mice fed NCD or HFD. (C) Percentage of live, singlet CD45+ cells and percentage of CD45+ B (B220+) and T (CD3e+) cells, from the SVF of VAT in WT and miR-146a-/- mice fed HFD. (D) Gene Sets significantly upregulated in miR-146a-/- HFD mice compared with WT, according to GSEA. (E) Gene sets significantly upregulated in miR-146a-/- NCD mice compared with WT, according to GSEA. NES = Seviteronel normalized enrichment score; FDR = false discovery rate, where FDR 0.25 is statistically significant. For a and b, p-values were calculated using two-tailed Students t-test. *p 0.05; ns = not significant.(TIF) pgen.1007970.s005.tif (1.7M) GUID:?906B9D99-CB27-43A4-9F4D-D45C98AAFDE6 S1 Table: Materials table listing all materials used in this publication. (PDF) pgen.1007970.s006.pdf (109K) GUID:?3E129077-F6A2-42DE-9AED-314FF462917B S2 Table: Underlying numeric data. (XLSX) pgen.1007970.s007.xlsx (89K) GUID:?DBFE75F1-DAB2-466D-A4A4-3B4105A56383 Data Availability StatementRaw RNA-Sequencing data have been uploaded to the GEO Repository and can be viewed here: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119703. The accession number is usually GSE119703. Abstract Identifying regulatory mechanisms that influence inflammation in metabolic tissues is critical for developing novel metabolic disease treatments. Here, we investigated the role of microRNA-146a (miR-146a) during diet-induced obesity in mice. miR-146a is usually reduced in obese and type 2 diabetic patients and our results reveal that miR-146a-/- mice fed a high-fat diet.The investigators were aware which mice were WT and miR-146a-/- mice, as the animal facility requires genotypes to be posted on cages. GUID:?ACEE7D7C-A5E8-48A8-9C8D-98FF4C4B1CC6 S2 Fig: miR-146a and BAT weight and gene expression. (A-C) qRT-PCR expression data from BAT samples of young, untreated WT (blue) or miR-146a-/- (green) mice relative to L32 expression in (A) BAT activation genes, (B) Lipogenesis genes, and (C) inflammatory immune genes. (D) Weight (g) of BAT samples from WT or miR-146a-/- mice. (E) qRT-PCR expression of miR-146a relative to 5s in WT (blue) or miR-146a-/- (green) BAT samples. (F) qRT-PCR expression data from BAT samples of WT (blue) or miR-146a-/- (green) mice following HFD, relative to L32 expression for a number of BAT and inflammatory genes. Data are shown as mean SEM (n = 5). p-value was calculated using two-tailed Students t-test. *p 0.05; **p 0.01.(TIF) pgen.1007970.s002.tif (507K) GUID:?AF3A5180-D10F-4DA6-AACE-48005E8EF8BE S3 Fig: miR-146a protects against high blood glucose levels during diet-induced obesity but does not alter pancreatic architecture. (A) WT and miR-146a-/- mice on NCD or HFD were injected with glucose at 0 minutes and blood glucose levels were measured over time for 120 minutes. (B) Blood glucose of 6-hour fasted WT and miR-146a-/- mice on NCD or HFD. (C) H&E staining of representative sections of pancreas at week 14 of diet treatment. Data are shown as meanSEM or as individual mice; p-value was calculated using two-tailed Students t-test. *p 0.05; **p 0.01.(TIF) pgen.1007970.s003.tif (2.2M) GUID:?26883EC6-0FA2-409D-AD1B-0109ED88656D S4 Fig: Increased weight gain by miR-146a-/- mice during DIO is not dependent upon miR-155. (A) Percent weight gain over KIFC1 time of diet in WT, miR-155-/-, miR-146a-/-, and DKO mice on HFD. (B) Body weight (in grams) of WT, miR-155-/-, miR-146a-/-, and DKO mice over time of diet. (C) Blood glucose levels of WT, miR-155-/-, miR-146a-/-, and DKO mice following a six-hour fast, at 15 weeks HFD. (D) Weight of reproductive, visceral fat pads harvested from WT, miR-155-/-, miR-146a-/-, and DKO mice following HFD. (E) TD-NMR body composition measurement showing percent body fat of WT, miR-155-/-, miR-146a-/- mice at week 14 HFD. (F) Percent lean mass of total body weight in WT, miR-155-/-, miR-146a-/-, and DKO mice at week 14 HFD. Data are shown as meanSEM (n = 5); p-value was calculated using two-tailed Students t-test. *p 0.05; **p 0.01; ***p 0.001; ****p 0.0001.(TIF) pgen.1007970.s004.tif (608K) GUID:?B15F5E2B-C4CD-4D56-A7E7-B5CF601903BE S5 Fig: GSEA of RNA-seq data from miR-146a-/- and WT mouse ATMs on NCD or HFD. (A) Percentages of live, singlet CD45+ cells positive for CD11b and F4/80 markers, collected from the SVF of VAT in WT and miR-146a-/- mice fed NCD or HFD. (B) Total number of live, singlet, CD45+ cells positive for CD11b and F4/80 markers, collected from the SVF of VAT in WT and miR-146a-/- mice fed NCD or HFD. (C) Percentage of live, singlet CD45+ cells and percentage of CD45+ B (B220+) and T (CD3e+) cells, from the SVF of VAT in WT and miR-146a-/- mice fed HFD. (D) Gene Sets significantly upregulated in miR-146a-/- HFD mice compared with WT, according to GSEA. (E) Gene sets significantly upregulated in miR-146a-/- NCD mice compared with WT, according to GSEA. NES = normalized enrichment score; FDR = false discovery rate, where FDR 0.25 is statistically significant. For a and b, p-values were calculated using two-tailed Students t-test. *p 0.05; ns = not significant.(TIF) pgen.1007970.s005.tif (1.7M) GUID:?906B9D99-CB27-43A4-9F4D-D45C98AAFDE6 S1 Table: Materials table listing all materials.p-values were calculated using two-tailed Students t-test. Jackson Laboratories were placed on HFD and the following were measured: (G) percent weight gain, (H) body weight gain (in grams), and (I) food consumption measured both day and night at 0, 3 and 18 weeks HFD in metabolic chambers. p-values were calculated using two-tailed Students t-test. *p 0.05; **p 0.01; ***p 0.001; ****p 0.0001.(TIF) pgen.1007970.s001.tif (745K) GUID:?ACEE7D7C-A5E8-48A8-9C8D-98FF4C4B1CC6 S2 Fig: miR-146a and BAT weight and gene expression. (A-C) qRT-PCR expression data from BAT samples of young, untreated WT (blue) or miR-146a-/- (green) mice relative to L32 expression in (A) BAT activation genes, (B) Lipogenesis genes, and (C) inflammatory immune genes. (D) Weight (g) of BAT samples from WT or miR-146a-/- mice. (E) qRT-PCR expression of miR-146a relative to 5s in WT (blue) or miR-146a-/- (green) BAT samples. (F) qRT-PCR expression data from BAT samples of WT (blue) or miR-146a-/- (green) mice following HFD, relative to L32 expression for a number of BAT and inflammatory genes. Data are shown as mean SEM (n = 5). p-value was calculated using two-tailed Students t-test. *p 0.05; **p 0.01.(TIF) pgen.1007970.s002.tif (507K) GUID:?AF3A5180-D10F-4DA6-AACE-48005E8EF8BE S3 Fig: miR-146a protects against high blood glucose levels during diet-induced obesity but does not alter pancreatic architecture. (A) WT and miR-146a-/- mice on NCD or HFD were injected with glucose at 0 minutes and blood glucose levels were measured over time for 120 minutes. (B) Blood glucose of 6-hour fasted WT and miR-146a-/- mice on NCD or HFD. (C) H&E staining of representative sections of pancreas at week 14 of diet treatment. Data are shown as meanSEM or as individual mice; p-value was calculated using two-tailed Students t-test. *p 0.05; **p 0.01.(TIF) pgen.1007970.s003.tif (2.2M) GUID:?26883EC6-0FA2-409D-AD1B-0109ED88656D S4 Fig: Increased weight gain by miR-146a-/- mice during DIO is not dependent upon miR-155. (A) Percent weight gain over time of diet in WT, miR-155-/-, miR-146a-/-, and DKO mice on HFD. (B) Body weight (in grams) of WT, miR-155-/-, miR-146a-/-, and DKO mice over time of diet. (C) Blood glucose levels of WT, miR-155-/-, miR-146a-/-, and DKO mice following a six-hour fast, at 15 weeks HFD. (D) Weight of reproductive, visceral fat pads harvested from WT, miR-155-/-, miR-146a-/-, and DKO mice following HFD. (E) TD-NMR body composition measurement showing percent body fat of WT, miR-155-/-, miR-146a-/- mice at week 14 HFD. (F) Percent lean mass of total body weight in WT, miR-155-/-, miR-146a-/-, and DKO mice at week 14 HFD. Data are shown as meanSEM (n = 5); p-value was calculated using two-tailed Students t-test. *p 0.05; **p 0.01; ***p 0.001; ****p 0.0001.(TIF) pgen.1007970.s004.tif (608K) GUID:?B15F5E2B-C4CD-4D56-A7E7-B5CF601903BE S5 Fig: GSEA of RNA-seq data from miR-146a-/- and WT mouse ATMs on NCD or HFD. (A) Percentages of live, singlet CD45+ cells positive for CD11b and F4/80 markers, collected from the SVF of VAT in WT and miR-146a-/- mice fed NCD or HFD. (B) Total number of live, singlet, CD45+ cells positive for CD11b and F4/80 markers, collected from the SVF of VAT in WT and miR-146a-/- mice fed NCD or HFD. (C) Percentage of live, singlet CD45+ cells and percentage of CD45+ B (B220+) and T (CD3e+) cells, from the SVF of VAT in WT and miR-146a-/- mice fed HFD. (D) Gene Sets significantly upregulated in miR-146a-/- HFD mice compared with WT, according to GSEA. (E) Gene sets significantly upregulated in miR-146a-/- NCD mice compared with WT, according to GSEA. NES = normalized enrichment score; FDR = false discovery rate, where FDR 0.25 is statistically significant. For a and b, p-values were determined using two-tailed College students t-test. *p 0.05; ns = not significant.(TIF) pgen.1007970.s005.tif (1.7M) GUID:?906B9D99-CB27-43A4-9F4D-D45C98AAFDE6 S1 Table: Materials table listing all materials used in this publication. (PDF) pgen.1007970.s006.pdf (109K) GUID:?3E129077-F6A2-42DE-9AED-314FF462917B S2 Table: Underlying numeric data. (XLSX) pgen.1007970.s007.xlsx (89K) GUID:?DBFE75F1-DAB2-466D-A4A4-3B4105A56383 Data Availability StatementRaw RNA-Sequencing data have been uploaded to the GEO Repository and may be viewed here: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119703. The accession quantity is definitely GSE119703. Abstract Identifying regulatory mechanisms that influence swelling in metabolic cells is critical.
